WO2015044698A3 - Medical composition containing a cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor - Google Patents

Medical composition containing a cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor Download PDF

Info

Publication number
WO2015044698A3
WO2015044698A3 PCT/HU2014/000089 HU2014000089W WO2015044698A3 WO 2015044698 A3 WO2015044698 A3 WO 2015044698A3 HU 2014000089 W HU2014000089 W HU 2014000089W WO 2015044698 A3 WO2015044698 A3 WO 2015044698A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition containing
inhibitor
cholesterol
interaction
active ingredient
Prior art date
Application number
PCT/HU2014/000089
Other languages
French (fr)
Other versions
WO2015044698A2 (en
Inventor
András FEHÉR
Zsolt ZSIGMOUND
György UJFALUSSY
Péter TONKA-NAGY
Ádám ORBÁN
Mónika AGYAGOS
Original Assignee
Egis Gyógyszergyár Zrt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gyógyszergyár Zrt. filed Critical Egis Gyógyszergyár Zrt.
Priority to EA201690666A priority Critical patent/EA034711B1/en
Priority to CN202111466045.4A priority patent/CN114796148A/en
Priority to CN201480061593.0A priority patent/CN105722505A/en
Priority to BR112016006888A priority patent/BR112016006888A2/en
Priority to MX2016004021A priority patent/MX2016004021A/en
Priority to UAA201603734A priority patent/UA120167C2/en
Priority to EP14800125.8A priority patent/EP3052088A2/en
Publication of WO2015044698A2 publication Critical patent/WO2015044698A2/en
Publication of WO2015044698A3 publication Critical patent/WO2015044698A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Abstract

The present invention is related to a pharmaceutical composition containing rosuvastatin and ezetimibe, wherein the interaction of the active ingredient and excipient is minimized, the active ingredients are present in spatially separated or contacting physical phases and wherein the active ingredient release from the two phases takes place in temporarily separated manner rather than occuring at the same time or begins delayed from one phase compared to the other, other. A further aspect of the present invention is method for decreasing an active ingredient- excipient interaction or interaction between active ingredients in combined pharmaceutical composition containing several solid phases produced by compression, which comprises adjusting the disintegration time of the compressed solid phases different from each other.
PCT/HU2014/000089 2013-09-30 2014-09-30 Medical composition containing a cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor WO2015044698A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EA201690666A EA034711B1 (en) 2013-09-30 2014-09-30 Medical composition containing a cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor
CN202111466045.4A CN114796148A (en) 2013-09-30 2014-09-30 Pharmaceutical composition containing cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor
CN201480061593.0A CN105722505A (en) 2013-09-30 2014-09-30 Medical composition containing a cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor
BR112016006888A BR112016006888A2 (en) 2013-09-30 2014-09-30 medical composition containing a cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor
MX2016004021A MX2016004021A (en) 2013-09-30 2014-09-30 Medical composition containing a cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor.
UAA201603734A UA120167C2 (en) 2013-09-30 2014-09-30 Medical composition containing a cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor
EP14800125.8A EP3052088A2 (en) 2013-09-30 2014-09-30 Medical composition containing a cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1300564A HU231036B1 (en) 2013-09-30 2013-09-30 Pharmaceutical composition comprising a cholesterol biosynthesis inhibitor and a cholesterol absorption inhibitor
HUP1300564 2013-09-30

Publications (2)

Publication Number Publication Date
WO2015044698A2 WO2015044698A2 (en) 2015-04-02
WO2015044698A3 true WO2015044698A3 (en) 2015-05-14

Family

ID=89991271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2014/000089 WO2015044698A2 (en) 2013-09-30 2014-09-30 Medical composition containing a cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor

Country Status (8)

Country Link
EP (1) EP3052088A2 (en)
CN (2) CN114796148A (en)
BR (1) BR112016006888A2 (en)
EA (1) EA034711B1 (en)
HU (1) HU231036B1 (en)
MX (1) MX2016004021A (en)
UA (1) UA120167C2 (en)
WO (1) WO2015044698A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
JP2017210455A (en) * 2016-05-27 2017-11-30 ニプロ株式会社 Ezetimibe-containing pharmaceutical composition
CZ2016539A3 (en) 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active substances and a method of its preparation
CZ2016538A3 (en) 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active ingredients
BR112022001783A2 (en) 2019-07-31 2022-03-22 Tecnimede Soc Tecnico Medicinal Sa Immediate release multi-unit solid oral compositions, their methods and uses.
GR1010183B (en) * 2020-12-14 2022-03-01 Elpen Αε Φαρμακευτικη Βιομηχανια, Solid pharmaceutical forms of atorvastatin and ezetimibe

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
WO2007119085A1 (en) * 2006-04-13 2007-10-25 Egis Gyógyszergyár Nyilvánosan Mukodo Reszvenytársaság Rosuvastatin zinc salt
WO2011010174A1 (en) * 2009-07-24 2011-01-27 Egis Gyógyszergyár Nyilvánosan Működő Crystalline form i rosuvastatin zinc salt
WO2011019326A2 (en) * 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
MX2012014970A (en) * 2012-12-18 2013-08-27 Hetlabs Mexico S A De C V Pharmaceutical compositions comprising ezetimibe and novel amorphous rosuvastatin calcium.
WO2013166117A1 (en) * 2012-05-01 2013-11-07 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008095263A1 (en) * 2007-02-09 2008-08-14 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
EP2204170A1 (en) * 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
ES2657708T3 (en) * 2009-07-28 2018-03-06 Egis Gyógyszergyár Zrt. New granulation and granulation procedure thus prepared
CN102357096A (en) * 2011-09-09 2012-02-22 北京阜康仁生物制药科技有限公司 Statins zinc salt-containing blood fat-reducing composite

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
WO2007119085A1 (en) * 2006-04-13 2007-10-25 Egis Gyógyszergyár Nyilvánosan Mukodo Reszvenytársaság Rosuvastatin zinc salt
WO2011019326A2 (en) * 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
WO2011010174A1 (en) * 2009-07-24 2011-01-27 Egis Gyógyszergyár Nyilvánosan Működő Crystalline form i rosuvastatin zinc salt
WO2013166117A1 (en) * 2012-05-01 2013-11-07 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
MX2012014970A (en) * 2012-12-18 2013-08-27 Hetlabs Mexico S A De C V Pharmaceutical compositions comprising ezetimibe and novel amorphous rosuvastatin calcium.

Also Published As

Publication number Publication date
UA120167C2 (en) 2019-10-25
EA201690666A1 (en) 2016-08-31
EA034711B1 (en) 2020-03-12
CN114796148A (en) 2022-07-29
BR112016006888A2 (en) 2017-08-01
WO2015044698A2 (en) 2015-04-02
CN105722505A (en) 2016-06-29
EP3052088A2 (en) 2016-08-10
HUP1300564A2 (en) 2015-04-28
MX2016004021A (en) 2016-09-06
HU231036B1 (en) 2019-12-30

Similar Documents

Publication Publication Date Title
WO2015044698A3 (en) Medical composition containing a cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor
WO2015018380A3 (en) Therapeutic nanoparticles and the preparation methods thereof
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
WO2011157722A3 (en) Solid ivabradine-containing composition
AU2012347200A8 (en) Tablet capable of combatting misuse by injection
WO2011122872A3 (en) Composition comprising coumestrol or a bean extract containing coumestrol
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
PH12017501397B1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
MX363699B (en) Co-micronisation product comprising ulipristal acetate.
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
MX2020012989A (en) Therapeutic agent for fibrosis.
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
PH12015500395A1 (en) Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
WO2010061220A3 (en) Novel processes and pure polymorphs
UA105285C2 (en) Solid pharmaceutical composition comprising ramipril and amlodipine besilate and method for its preparation
MX2014014579A (en) O/w-emulsion-type topical pharmaceutical compositions containing a retinoid.
WO2012077968A3 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
WO2014159501A3 (en) Processes for preparing tetrahydroisoquinolines
WO2014007549A3 (en) Composition for preventing or treating colitis comprising s-allyl-l-cysteine as active ingredient, and medical preparation comprising same
WO2015160249A3 (en) Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation
MX2013015272A (en) Micronized crystals of atorvastatin hemicalcium.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/004021

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: A201603734

Country of ref document: UA

REEP Request for entry into the european phase

Ref document number: 2014800125

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016006888

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2014800125

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201690666

Country of ref document: EA

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14800125

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112016006888

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160329